Pharmaceutical Composition Containing Neonatal Pig-Derived Mesenchymal Stem Cells for Treating Non-Porcine Animals
Summary
USPTO published patent application US20260097081A1 by Fukuoka University for a pharmaceutical composition containing neonatal pig-derived mesenchymal stem cells. The cells produce at least one humoral factor selected from TGF-β1, TGF-β2, VEGF-A, and VEGF-C for therapeutic use in treating cardiovascular conditions, wounds, and decubitus in non-porcine animals. The application was filed on October 10, 2025.
What changed
USPTO published a patent application (US20260097081A1) for a pharmaceutical composition containing neonatal pig-derived mesenchymal stem cells. The invention claims therapeutic uses including treatment of cardiovascular disease, wounds, and decubitus through production of humoral factors TGF-β1, TGF-β2, VEGF-A, and VEGF-C.
For pharmaceutical and biotechnology companies, this application signals Fukuoka University's entry into the stem cell therapy space using xenogeneic cell sources. Parties developing competing mesenchymal stem cell products or exploring pig-derived cell therapies should evaluate potential freedom-to-operate implications and the competitive landscape for regenerative medicine approaches.
What to do next
- Monitor for patent grant status
- Review therapeutic applications for competitive landscape
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PHARMACEUTICAL COMPOSITION
Application US20260097081A1 Kind: A1 Apr 09, 2026
Assignee
FUKUOKA UNIVERSITY
Inventors
Shohta KODAMA, Masuhiro Nishimura, Shinichi Matsumoto, Osamu Sawamoto
Abstract
An object of the present invention is to provide a pharmaceutical composition containing mesenchymal stem cells that exhibit excellent therapeutic effects on various diseases, injured parts, wounds and decubitus. The present invention relates to a pharmaceutical composition for treating a non-porcine animal, the pharmaceutical composition includes a neonatal pig-derived mesenchymal stem cell which produces at least one humoral factor selected from TGF-β1, TGF-β2, VEGF-A and VEGF-C.
CPC Classifications
A61K 35/28 A61P 9/10 A61P 17/02
Filing Date
2025-10-10
Application No.
19355935
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.